In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

In the trials, tirzepatide (Mounjaro, Eli Lilly) was associated with a mean weight loss of about 26% in both trials, with a safety profile similar to that previously reported in other SURMOUNT ...

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, ...

Impact of lead-in phases and sex on weight loss outcomes. While the SM-1 and SM-2 trials involved randomization immediately after a screening period, SM-3 had a 12-week lead-in phase with ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

The analyses found that across all trials, tirzepatide treatment was associated with significant weight reduction compared to placebo, regardless of sex—ranging from -11.5% to -27.6% in females ...

2. Individuals with Type 2 Diabetes Looking for Weight Loss Solutions . Given tirzepatide’s approval for the treatment of type 2 diabetes, patients with this condition who are also seeking to ...

In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9 percent with early and late discontinuation and nondiscontinuation, respectively.